{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:06:17Z","timestamp":1792850777291,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.soc.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:48:52Z","timestamp":1744480132000},"page":"145-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Precision Oncology in Pancreatic Cancer and Future Treatment Directions"],"prefix":"10.1016","volume":"35","author":[{"given":"Layal","family":"Al Mahmasani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.soc.2025.03.002_bib1","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.soc.2025.03.002_bib2","series-title":"American cancer society. Cancer facts & figures","year":"2025"},{"issue":"10","key":"10.1016\/j.soc.2025.03.002_bib3","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.3390\/biomedicines12102175","article-title":"Targeted therapies in pancreatic cancer: a new era of precision medicine","volume":"12","author":"Li","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.soc.2025.03.002_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: the critical Driver and therapeutic Target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.soc.2025.03.002_bib5","first-page":"1","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","author":"Varghese","year":"2025","journal-title":"Nat Med"},{"issue":"7540","key":"10.1016\/j.soc.2025.03.002_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"7378","key":"10.1016\/j.soc.2025.03.002_bib7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.soc.2025.03.002_bib8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2025.03.002_bib9","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"10409","key":"10.1016\/j.soc.2025.03.002_bib10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.soc.2025.03.002_bib11","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2025.03.002_bib12","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1245\/s10434-020-08469-8","article-title":"Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer","volume":"27","author":"Golan","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.03.002_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.soc.2025.03.002_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.soc.2025.03.002_bib15","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.soc.2025.03.002_bib16","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II Study of maintenance Rucaparib in patients with platinum-sensitive advanced pancreatic Cancer and a pathogenic Germline or somatic Variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.03.002_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"issue":"6349","key":"10.1016\/j.soc.2025.03.002_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.soc.2025.03.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2025.03.002_bib20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.03.002_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.soc.2025.03.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0611","article-title":"Ipilimumab\/nivolumab Therapy in patients with metastatic Pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants","volume":"8","author":"Terrero","year":"2022","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.03.002_bib23","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2024.3651","article-title":"Lynch syndrome and somatic mismatch repair variants in pancreas cancer","volume":"10","author":"O\u2019Connor","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.03.002_bib24","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.soc.2025.03.002_bib25","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.soc.2025.03.002_bib26","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.22.02770","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer Institute of Canada clinical trials group","volume":"41","author":"Moore","year":"2023","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.soc.2025.03.002_bib27","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1200\/JCO.22.02630","article-title":"Nimotuzumab plus gemcitabine for K-ras wild-type locally advanced or metastatic pancreatic cancer","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.03.002_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.soc.2025.03.002_bib29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2025.03.002_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2025.03.002_bib31","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.03.002_bib32","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.18632\/oncotarget.2972","article-title":"Molecular landscape of pancreatic cancer: implications for current clinical trials","volume":"6","author":"Heestand","year":"2015","journal-title":"Oncotarget"},{"issue":"33","key":"10.1016\/j.soc.2025.03.002_bib33","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2025.03.002_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00280-021-04234-0","article-title":"BRAF\/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series","volume":"87","author":"Butt","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.soc.2025.03.002_bib35","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2025.03.002_bib36","unstructured":"National comprehensive cancer network. V. 1.2025. Pancreatic adenocarcinoma."},{"issue":"7424","key":"10.1016\/j.soc.2025.03.002_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"issue":"7781","key":"10.1016\/j.soc.2025.03.002_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.soc.2025.03.002_bib39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2025.03.002_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p. G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.soc.2025.03.002_bib41","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS G12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.03.002_bib42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"issue":"12_Supplement","key":"10.1016\/j.soc.2025.03.002_bib43","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1158\/1538-7445.AM2022-2667","article-title":"Trial in progress: phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation","volume":"82","author":"Waizenegger","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2025.03.002_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2025.03.002_bib45","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8_Supplement","key":"10.1016\/j.soc.2025.03.002_bib46","doi-asserted-by":"crossref","first-page":"CT229","DOI":"10.1158\/1538-7445.AM2023-CT229","article-title":"Abstract CT229: CRESTONE: a Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors","volume":"83","author":"Patil","year":"2023","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.soc.2025.03.002_bib47","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2022.40.16_suppl.3006","article-title":"CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions","volume":"40","author":"Carrizosa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.03.002_bib48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion\u2013positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.soc.2025.03.002_bib49","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.soc.2025.03.002_bib50","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7592","key":"10.1016\/j.soc.2025.03.002_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.soc.2025.03.002_bib52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.2019.37.4_suppl.188","article-title":"Integrative molecular profiling and response to chemotherapy on the COMPASS trial","volume":"37","author":"O\u2019Kane","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.soc.2025.03.002_bib53","doi-asserted-by":"crossref","first-page":"LBA4004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4004","article-title":"Early results of the PASS-01 trial: pancreatic adenocarcinoma signature stratification for treatment-01","volume":"42","author":"Knox","year":"2024","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.soc.2025.03.002_bib54","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jmoldx.2024.07.002","article-title":"Purity independent subtyping of tumors (PurIST) pancreatic cancer classifier: analytic validation of a 16-RNA expression signature distinguishing basal and classical subtypes","volume":"26","author":"Li","year":"2024","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1016\/j.soc.2025.03.002_bib55","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.soc.2025.03.002_bib56","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.soc.2025.03.002_bib57","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.soc.2025.03.002_bib58","author":"Spira","year":"2025","journal-title":"American Society of Clinical Oncology"},{"key":"10.1016\/j.soc.2025.03.002_bib59","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","article-title":"608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2025.03.002_bib60","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1838","article-title":"652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI (ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)","volume":"34","author":"Arbour","year":"2023","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.soc.2025.03.002_bib61","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.soc.2025.03.002_bib62","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","article-title":"Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer","volume":"42","author":"McIntyre","year":"2024","journal-title":"Cancer Cell"},{"issue":"1\u20133","key":"10.1016\/j.soc.2025.03.002_bib63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17474124.2024.2322648","article-title":"Next-generation therapies for pancreatic cancer","volume":"18","author":"Buckley","year":"2024","journal-title":"Expet Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.soc.2025.03.002_bib64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.omto.2023.08.011","article-title":"Claudin18. 2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer","volume":"30","author":"Liu","year":"2023","journal-title":"Molecular Therapy-Oncolytics"},{"issue":"7","key":"10.1016\/j.soc.2025.03.002_bib65","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4251\/wjgo.v14.i7.1252","article-title":"Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma","volume":"14","author":"Wang","year":"2022","journal-title":"World J Gastrointest Oncol"},{"issue":"16_suppl","key":"10.1016\/j.soc.2025.03.002_bib66","doi-asserted-by":"crossref","first-page":"e16012","DOI":"10.1200\/JCO.2024.42.16_suppl.e16012","article-title":"Outstanding safety and efficacy data of IMC002, an autologous CLDN18.2-targeting CAR-T, in CLDN18.2+ advanced solid tumors","volume":"42","author":"Luo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2025.03.002_bib67","doi-asserted-by":"crossref","first-page":"S934","DOI":"10.1016\/j.annonc.2024.08.1595","article-title":"1532TiP Zolbetuximab with gemcitabine+ nab-paclitaxel (GN) in first-line treatment of Claudin 18.2\u2013positive metastatic pancreatic cancer (mPC): phase II, open-label, randomized study","volume":"35","author":"Park","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2025.03.002_bib68","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1200\/JCO.2024.42.16_suppl.4011","article-title":"Safety and efficacy of IBI389, an anti-CLDN18. 2\/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: preliminary results from a phase 1 study","volume":"42","author":"Hao","year":"2024","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.soc.2025.03.002_bib69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.soc.2025.03.002_bib70","doi-asserted-by":"crossref","first-page":"105492","DOI":"10.1016\/j.jbc.2023.105492","article-title":"Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition","volume":"300","author":"Bedard","year":"2024","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.soc.2025.03.002_bib71","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.03.002_bib72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.soc.2025.03.002_bib73","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7_Supplement","key":"10.1016\/j.soc.2025.03.002_bib74","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1538-7445.AM2023-3395","article-title":"Clinical impact of FGFR inhibitors on FGFR2 positive pancreatic cancer","volume":"83","author":"Stein","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2025.03.002_bib75","doi-asserted-by":"crossref","first-page":"S898","DOI":"10.1016\/j.annonc.2023.09.2570","article-title":"1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: single-arm RAGNAR trial","volume":"34","author":"Pant","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.03.002_bib76","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.03.002_bib77","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2025.03.002_bib78","unstructured":"Therapeutics, E., First in human phase 1\/2 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma and other solid tumors. clinicaltrials. gov, 2021."},{"issue":"2","key":"10.1016\/j.soc.2025.03.002_bib79","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"issue":"7963","key":"10.1016\/j.soc.2025.03.002_bib80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.soc.2025.03.002_bib81","first-page":"1","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.soc.2025.03.002_bib82","unstructured":"Silexion therapeutics announces significant new data from phase 2 trial of LODER\u2122 in non-resectable pancreatic cancer. 2025."}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:58:45Z","timestamp":1763762325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1055320725000249"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.03.002","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Oncology in Pancreatic Cancer and Future Treatment Directions","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}